DK0939767T3 - Procin faktor VIII og hybrider deraf - Google Patents

Procin faktor VIII og hybrider deraf

Info

Publication number
DK0939767T3
DK0939767T3 DK97933180T DK97933180T DK0939767T3 DK 0939767 T3 DK0939767 T3 DK 0939767T3 DK 97933180 T DK97933180 T DK 97933180T DK 97933180 T DK97933180 T DK 97933180T DK 0939767 T3 DK0939767 T3 DK 0939767T3
Authority
DK
Denmark
Prior art keywords
factor viii
procin
hybrids
modified factor
viii proteins
Prior art date
Application number
DK97933180T
Other languages
English (en)
Inventor
John S Lollar
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK0939767T3 publication Critical patent/DK0939767T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
DK97933180T 1996-06-26 1997-06-26 Procin faktor VIII og hybrider deraf DK0939767T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/670,707 US5859204A (en) 1992-04-07 1996-06-26 Modified factor VIII

Publications (1)

Publication Number Publication Date
DK0939767T3 true DK0939767T3 (da) 2006-10-09

Family

ID=24691532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97933180T DK0939767T3 (da) 1996-06-26 1997-06-26 Procin faktor VIII og hybrider deraf

Country Status (12)

Country Link
US (1) US5859204A (da)
EP (2) EP1561757A1 (da)
JP (2) JP3611860B2 (da)
AT (1) ATE328896T1 (da)
AU (1) AU717686B2 (da)
CA (1) CA2258502C (da)
DE (1) DE69736068T2 (da)
DK (1) DK0939767T3 (da)
ES (1) ES2267146T3 (da)
HK (1) HK1022480A1 (da)
PT (1) PT939767E (da)
WO (1) WO1997049725A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
CA2434097A1 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
JP4634036B2 (ja) * 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
EP1682106A4 (en) * 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
ES2449044T3 (es) 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
BRPI0811293A2 (pt) * 2007-05-07 2017-05-16 Peptimmune Inc métodos para a expansão direta de epítopos para uso com ligantes de anticorpo.
CA2703948A1 (en) 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
LT2506868T (lt) 2009-12-06 2018-02-26 Bioverativ Therapeutics Inc. Faktoriaus viii-fc chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP5826772B2 (ja) * 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
EP2536754A1 (en) 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
SG190136A1 (en) 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
CA2841066C (en) 2011-07-08 2023-09-26 Biogen Idec Hemophilia Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
WO2013106787A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
PL2882450T3 (pl) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2014209942A1 (en) 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
IL282168B2 (en) 2014-01-10 2023-03-01 Bioverativ Therapeutics Inc Factor viii chimeric proteins and their uses
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
JP2024511851A (ja) 2021-03-30 2024-03-15 エーエーブイネルジーン インク． 改変血漿凝固第ｖｉｉｉ因子およびその使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5149637A (en) * 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003191A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties

Also Published As

Publication number Publication date
AU3643397A (en) 1998-01-14
JP3611860B2 (ja) 2005-01-19
JP2000513934A (ja) 2000-10-24
EP0939767B1 (en) 2006-06-07
WO1997049725A9 (en) 2005-11-17
CA2258502C (en) 2003-04-29
EP1561757A1 (en) 2005-08-10
DE69736068D1 (de) 2006-07-20
HK1022480A1 (en) 2000-08-11
WO1997049725A1 (en) 1997-12-31
PT939767E (pt) 2006-10-31
ATE328896T1 (de) 2006-06-15
DE69736068T2 (de) 2006-12-14
AU717686B2 (en) 2000-03-30
ES2267146T3 (es) 2007-03-01
EP0939767A1 (en) 1999-09-08
US5859204A (en) 1999-01-12
EP0939767A4 (en) 2001-04-04
JP3683897B2 (ja) 2005-08-17
CA2258502A1 (en) 1997-12-31
JP2004141173A (ja) 2004-05-20

Similar Documents

Publication Publication Date Title
DK0939767T3 (da) Procin faktor VIII og hybrider deraf
DK1490386T3 (da) Nyt polypeptid og nukleinsyrer kodende for dette
NO980255D0 (no) Antiparasittiske marcfortiner og paraherkvamider
TR200100056T2 (tr) Nörotrofik faktörler
DE69534778D1 (en) Cathepsin-02-protease
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
ATE207140T1 (de) Elektrolyseapparat zur herstellung von halogengasen
ATE247719T1 (de) Mittel zur herstellung von leder
EP0749496A4 (en) HUMAN DNA MALFUNCTION REPAIR PROTEINS
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
ZA9710288B (en) Novel genes encoding telomerase proteins.
DE69622051T2 (de) Verfahren zur herstellung von 2,4-dihydroxy-pyridin und 2,4-dihydroxy-3-nitropyridin
DK0920501T3 (da) Neuritin, et neurogen
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ATE252112T1 (de) Prozess zur herstellung von aza zyclohexapeptide
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE69532725D1 (de) Methode zur direkter klonierung von nukleasegenen in e.coli
IS4957A (is) Hreinsuð prótein, samskeyttar DNA raðir og aðferðir til að stýra þroskun kaffiplantna
CY1105287T1 (el) Ορχεως - ειδικη ανθρωπινη svph1-8 πρωτεϊναση
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
PE20399A1 (es) Muteina ob
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
NO991227D0 (no) PTX-sensitive G-proteiner, deres fremstilling og bruk
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
DE59702788D1 (de) Verfahren zur herstellung von 4,6-diamino-resorcin-dihydrochlorid